US EditionCalidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and ...
Summary by Hastings Tribune
1 Articles
1 Articles
All
Left
Center
1
Right
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and ...
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, today announced the presentation of its…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
